Financial Performance - In 2024, the company achieved a revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - The net profit excluding non-recurring items was 4.523 billion CNY, reflecting a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, a growth of 22.68% [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were 2.66 CNY, up 16.16% [2] Business Structure and Efficiency - The industrial revenue accounted for 36.14% of total revenue, with an industrial revenue growth rate of 5.30% [2] - The industrial gross profit margin was 65.93%, an increase of 1.69 percentage points [3] - Sales expenses decreased by 2.26% and management expenses decreased by 1.98% compared to the previous year [3] Pharmaceutical Division Performance - The pharmaceutical business group generated 6.924 billion CNY in revenue, a year-on-year increase of 11.8% [4] - The sales revenue of Yunnan Baiyao aerosol exceeded 2.1 billion CNY, growing over 26% [4] - Other traditional Chinese medicine products, such as Pudilan Xiaoyan Pian, saw significant growth, with sales nearing 200 million CNY, up over 22% [4] Oral Care Products - Yunnan Baiyao toothpaste maintained the top market share in the domestic oral care sector [5] - During major sales events, Yunnan Baiyao's oral health brand consistently ranked first in online channels [5] - The brand's marketing initiatives reached over 6.43 billion exposures [6] Emerging Business Units - The medical device division generated 425 million CNY in revenue, a 61% increase [7] - The health supplement division achieved 99.07 million CNY in revenue, growing 101% and marking its first profitable year [7] - The Sanqi product line saw rapid growth through unified packaging upgrades and comprehensive marketing strategies [7]
云南白药(000538) - 2025年4月7日调研活动附件之投资者调研会议记录(一)